Zydus seeks DCGI’s approval for conducting clinical trials of its COVID-19 biological therapy :
Zydus Cadila has recently sought the DCGI’s approval for conducting clinical trials of its new COVID-19 treatment. This is a monoclonal antibody (mAb) based cocktail that can neutralize COVID-19 infection. 1
The pharma firm stated that the antibodies are made by cloning unique white blood cells. This biological therapy, called ZRC-3308, is specially developed by Zydus using two SARS-CoV-2 neutralizing monoclonal antibodies. It is expected to be mainly used for treating mild COVID-19.
EUA is often granted in the US, Europe, and India for treatments that target the SARS-CoV-2 spike protein or are based on neutralizing mAbs. This is attributed to the fact that such treatments reduce the viral load and decrease the risk of hospitalization.
Variant strains can be better handled using cocktails of two mAbs rather than a single-mAb based product. This is because the latter tends to lose its efficacy when exposed to rapidly generating variants.
Zydus seeks DCGI’s approval.
The company’s Managing Director revealed that ZRC-3308 is a safe treatment option. He firmly believes that this combination would reduce the patient’s suffering and discomfort.
ZRC – 3308 targets two unique epitopes on the spike protein of the SARS-CoV-2. The mAbs of this therapy are designed to provide much longer protection than the currently approved products. The company also stated that this design reduces the risk of severe disease by preventing the progression of tissue damage.
In 2020, Biocon’s mAb Itolizumab was granted “restricted emergency use” by DCGI to treat COVID – 19. This antibody was originally used to cure psoriasis. The USFDA, too, granted the EUA to Eli Lilly’s bamlanivimab (LY – CoV555) to treat mild to moderate COVID – 19 patients. It was also permitted for use in some pediatric patients. This authorization was revoked later on as it was ineffective against the variants of the virus.
- 1. Drugs Controller General of India.
- 2. Severe Acute Respiratory Syndrome Coronavirus 2019.
- 3. Emergency Use Authorization.
- 4. United States Food and Drug Administration.
- Pharma News August 2021
- Monthly Update- pharma News July 2021
- Moderna collaborates with Thermo Fischer Scientific
- Bamlanivimab and Etesevimab: EUA in India
- JB Chemicals launches NOSMOK nicotine lozenges
- 2-DG: anti-COVID-19 by the INMAS
- GSK and Vir Biotechnology plan to launch Sotrovimab
- USFDA approves Gland Pharma’s Foscarnet
- Gilead delivers Amphotericin B to India
- Monthly Update- pharma News June 2021
- Zydus seeks DCGI’s approval for COVID-19 biological therapy
- Zydus and TLC to commercialize AmphoTLC in India
- Sun Pharma recalls Metformin tablets from the US market
- Pfizer – BioNTech pledge to supply 2 billion doses
- Johnson & Johnson COVID Vaccine update
- Jubilant, Sun, and Lupin initiated products recall
- USFDA approves Gland Pharma’s Foscarnet Injection
- NMPA approves Tagrisso as an adjuvant therapy in early–stage lung cancer.
- Vaccination drive in South Korea
- VAV Lifesciences: mRNA – based vaccine supply chain
- Remdesivir with NDDS: Jubilant seeks approval
- J&J COVID vaccine to begin clinical trials
- Sputnik V: RDIF to manufacture 100 million doses
- ISSAR pharma licenses its New Chemical Entities
- IDT Biologika agrees to produce Astra’s COVID vaccine